BridgeMD
Tests treatment safety and results for Parkinson Disease (PD)
Official title Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease
ClinicalTrials.gov ID: NCT07572071
What this study is testing
What is Dopacell?
Dopacell is an investigational medicine, being studied as a potential treatment for parkinson disease (pd).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 70
You may be able to join if
- Age: 30-70 years
- Diagnosis of PD: MDS clinical Diagnostic Criteria for Parkinson's disease
- The disease duration more than 5 years
- Moderate Parkinson's disease, defined as a Hoehn and Yahr stage of 2 or 3 during the OFF period.
- The patient is receiving oral pharmacological therapy, and in the opinion of the Principal Investigator, the patient's symptoms remain inadequately...
You likely can't join if
- The abnormal function of immune system
- The symptomatic brain injuries (brain atrophy, cerebral Infarct, trauma, vascular malformation) confirmed by brain MRI
- Markedly reduced or normal signal in the ventral striatum on TRO-DaT SPECT imaging.
- Any abnormal findings on brain MRI.
- Positive GBA mutation test.
- Diagnosis of dementia based on a MoCA score \< 24.
See the full eligibility criteria
- Age: 30-70 years
- Diagnosis of PD: MDS clinical Diagnostic Criteria for Parkinson's disease
- The disease duration more than 5 years
- Moderate Parkinson's disease, defined as a Hoehn and Yahr stage of 2 or 3 during the OFF period.
- The patient is receiving oral pharmacological therapy, and in the opinion of the Principal Investigator, the patient's symptoms remain inadequately controlled despite optimal medical management, or the patient is...
- No history or only mild levodopa-induced dyskinesia, defined as a score of 2 or less on the UDysRS scale in any body region during the ON state.
- The patient demonstrates a clinically meaningful response to a therapeutic dose of levodopa, as determined by the Principal Clinical Investigator or a trained specialist under the supervision of the Principal...
- The performance of different organs based on laboratory evaluations:
- Number of neutrophils ≥2000 / microliter
- Platelet count ≥100,000 / microliter
- AST / ALT: less than or equal to three times the maximum normal value at the intervention site
- Total bilirubin less than or equal to 1.5 times the maximum normal amount at the intervention site
- eGFR \ rate: greater than or equal to 60 ml / min / 1.73 m2 \ eGFR (mL / min / 1.73 m2) = 194 X Cr \^ -1.094 X age \^ -0.287 (X 0.739 for females)
- Informed consent
- The abnormal function of immune system
- The symptomatic brain injuries (brain atrophy, cerebral Infarct, trauma, vascular malformation) confirmed by brain MRI
- Markedly reduced or normal signal in the ventral striatum on TRO-DaT SPECT imaging.
- Any abnormal findings on brain MRI.
- Positive GBA mutation test.
- Diagnosis of dementia based on a MoCA score \< 24.
- The abnormality of thrombotic system or high risk of bleeding
- Positive for any of the following viral markers or active infections: HBsAg, HBsAb, HBcAb, anti-HIV antibodies, anti-HTLV-1\&2 antibodies, active hepatitis C infection, syphilis, or active CMV, VZV, EBV, or COVID-19...
- Impossibility of MRI imaging for patients with metal in the body, pacemaker in the body, claustrophobia, with artificial heart valves that are incompatible with MRI or body weight is not within the tolerable range for...
- Patients with contraindications to the study drug: Tacrolimus, Prednisolone, Basiliximab, Cotrimoxazole, MRI contrast agent.
- Patients undergoing other cell transplants, including embryonic stem cell-derived dopaminergic progenitor cells.
- Patients with a history of PD at the same time and concurrent: Malignant neoplasm, epilepsy, cerebral hemorrhage or a positive history
- Psychiatric disorders confirmed by a psychiatrist, including major depression, bipolar disorder, or schizophrenia, that are uncontrolled or treatment resistant.
- Patients with intellectual disability who, in the judgment of a psychiatrist, are unable to fully comprehend the study requirements.
- History of pallidotomy, thalamotomy, or deep brain stimulation (DBS).
- Patients considered high-risk candidates for surgery, particularly neurosurgery or DBS implantation, due to significant cardiovascular, pulmonary, or other systemic comorbidities identified during preoperative...
- Patients who have a history of taking the following in the three months prior to enrollment: Immunosuppressant, antipsychotic drug, anticonvulsant drugs or anticoagulant therapy (if discontinuation or perioperative...
- History of Apomorphine use
- History of chronic alcohol use or illicit drug abuse.
- Patients who are pregnant, lactating, or people who did not avoid pregnancy during the study.
- Patients who, according to the researchers' opinions, are not suitable for safe study.
The study team makes the final eligibility decision.
Where it's taking place
- Shiraz, Iran
- Tehran, Iran
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shiraz, Iran; Tehran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.